Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective
This large, retrospective real-world analysis supports the hypothesis that the alternative, partially lower pembrolizumab dosing protocol in NSCLC maintains treatment effectiveness while reducing treatment costs.
Authors
- Peter G. M. Mol (ORCID: https://orcid.org/0000-0002-4262-3180)
- Ruben Malmberg (ORCID: https://orcid.org/0009-0004-9004-0547)
- J. Zwaveling (ORCID: https://orcid.org/0000-0002-6080-6183)
- Job F. H. Eijsink (ORCID: https://orcid.org/0000-0001-5442-0789)
- Geeske F. Grit (ORCID: https://orcid.org/0009-0006-1734-7950)
- Hans J.M. Smit (ORCID: https://orcid.org/0000-0003-0224-6808)
- Pim Gal (ORCID: https://orcid.org/0000-0001-7622-9029)
- Anne M. P. Eldering-Heldens
- Pepijn Brocken
- Esther Dronkers (ORCID: https://orcid.org/0000-0002-3556-9104)
- Stefan Böhringer (ORCID: https://orcid.org/0000-0001-9108-9212)
- Roelof van Leeuwen
- Doranne L. Hilarius (ORCID: https://orcid.org/0000-0001-6638-9467)
- Eva Jaarsma
- Regine Jhm van Drie-Pierik
- Esmée van Geffen
- A.N.M. Wymenga
Institutions
- University Medical Center Groningen (NL)
- Leiden University Medical Center (NL)
- Medisch Spectrum Twente (NL)
- Noordwest Ziekenhuisgroep (NL)
- Rode Kruis Ziekenhuis (NL)
- Dutch Institute for Clinical Auditing (NL)
- Medex Healthcare Research (US)
- Haga Hospital (NL)
- Isala (NL)
- Erasmus MC Cancer Institute (NL)
- Rijnstate Hospital (NL)
Publication Details
- Journal
- Lung Cancer
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1016/j.lungcan.2024.107950
- Citations
- 11
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.11
Funders
- European Commission
- HORIZON EUROPE Framework Programme